CorpDigest
Bayer AG
Leadership History
5 leaders · Full leadership timeline
Last reviewed: 2025-07-15 · By Swet Parvadiya
Bayer AG is burning through $4.8 billion annually in special charges—primarily for Roundup litigation, restructuring, and impairments—while its market capitalization of $38.7 billion has fallen below the $66 billion it paid for Monsanto in 2018, making the acquisition the worst corporate deal in German history and leaving the 162-year-old company's entire enterprise valued at less than the purchase price of a single division. CEO Bill Anderson, the first American to lead Bayer, has cut over 12,000 positions, halved management ranks, and slashed the dividend to the legal minimum of $0.1 per share in a desperate bid to execute a five-priority transformation before litigation costs and generic erosion force a breakup of the conglomerate. With Nubeqa reaching $1.7 billion in sales (+78% YoY) and Kerendia growing 67%, the pharmaceuticals pipeline shows genuine promise, but Xarelto's accelerating generic decline and Crop Science's 19% glyphosate sales collapse create a revenue valley that new products cannot yet fill.
Chairman and Managing Director
Friedrich Bayer Jr., son of the founder, joined the company as a chemist in 1873 and became the driving force behind its scientific expansion. He led the diversification from dyestuffs into pharmaceuticals, culminating in the 1899 launch of Aspirin, and oversaw the company's growth into a global chemical enterprise before his death in 1920.
Chairman and Managing Director
Carl Duisberg joined Bayer in 1888 and became the dominant figure in its expansion. He led the development of Aspirin into a global brand, established Bayer's first foreign subsidiaries, and was the architect of the 1925 merger into IG Farben. His leadership transformed Bayer from a regional dyestuffs maker into an international chemical conglomerate.
Chairman of the Board of Management
Wenning led Bayer's strategic transformation from a diversified chemical conglomerate to a focused life sciences company. He oversaw the 2006 Schering acquisition and initiated the process that led to the 2015 Covestro spin-off, establishing the three-division structure that defines Bayer today.
Chairman of the Board of Management and CEO
Baumann championed and executed the $66 billion Monsanto acquisition, the largest in German corporate history. He defended the deal against shareholder criticism and managed the initial litigation response, including the $10.9 billion settlement. He stepped down in 2023 after the company's market value declined by over 60% during his tenure.
Chairman of the Board of Management and CEO
Anderson, the first American CEO in Bayer's 162-year history, launched the Dynamic Shared Ownership transformation, cutting over 12,000 positions and halving management ranks. He has prioritized pharmaceuticals pipeline development (Nubeqa, Kerendia), Crop Science profitability, balance sheet deleveraging, and litigation containment. His contract was extended through March 2029 by unanimous Supervisory Board decision.
The most immediate threat to Bayer's margin and market position is the accelerating generic erosion of Xarelto (rivaroxaban), the oral anticoagulant that was once the company's largest pharmaceutical revenue generator. Xarelto sales declined markedly in 2024 as generic competitors entered European and Canadian markets, and the company has acknowledged that erosion will be 'more acute in 2026' as additional markets face patent expiry. The product generated license revenues in the United States at prior-year levels because Janssen (Johnson & Johnson) markets it there, but this revenue stream is also time-limited. The loss of Xarelto revenue—historically exceeding $5.5 billion annually—creates a gap that new products like Nubeqa ($1.7 billion in 2024) and Kerendia (smaller but growing at 67%) cannot fully fill in the near term. The product mix shift within Pharmaceuticals is therefore working against margin: declining high-margin Xarelto sales are being replaced by growing but lower-margin new launches that require heavy marketing investment. The Crop Science division faces a parallel structural challenge. Glyphosate sales fell 19% year-over-year in 2024 due to price competition from Chinese generic manufacturers who have flooded the market with low-cost alternatives. This is not a cyclical downturn but a permanent structural shift: the glyphosate molecule is off-patent, and Chinese producers with lower cost structures can undercut Bayer on price while maintaining acceptable quality. The corn seed business showed strength, but overall Crop Science EBITDA margins of 19.4% are insufficient to justify the capital intensity of the business. Regulatory headwinds are intensifying: the European Union's Farm to Fork strategy aims to reduce chemical pesticide use by 50% by 2030, and individual member states (Germany, France) have imposed or are considering glyphosate bans. The German government, in a remarkable irony given Bayer's German heritage, has pushed for stricter glyphosate restrictions than the EU average. The litigation overhang is the single most consequential challenge and the primary driver of investor skepticism. The Roundup glyphosate cases have generated over 165,000 claims in the United States since the Monsanto acquisition. Bayer settled approximately 113,000 claims for $10.9 billion in 2020, but new claims continue emerging. The company recorded $6.0 billion in litigation-related expenses in 2025 alone, bringing total provisions to over $17.4 billion since 2018. The Supreme Court declined to hear Bayer's appeal of a $25 million Hardeman verdict in 2022, eliminating the most promising path to a favorable federal precedent. The company now faces a multi-pronged strategy: managing individual cases, negotiating class action settlements, and lobbying for legislative reforms to cap punitive damages. But each quarter of litigation uncertainty depresses the stock price and constrains management's strategic options. The Xarelto patent litigation adds further pharmaceutical-specific legal risk, with increased costs recorded in 2024 'mainly related to Xarelto patents.' The Dicamba drift lawsuits—alleging that Monsanto's dicamba herbicide damaged neighboring crops—have generated additional claims. PCB pollution cases, talc-related liabilities, and One A Day vitamin lawsuits create a portfolio of legal exposures that management must navigate simultaneously. The balance sheet challenge is severe. Net financial debt of approximately $36.0 billion as of December 2024, against a market capitalization of $38.7 billion, means Bayer is essentially valued at its debt level. The debt-to-equity ratio of 134.27% is high for a pharmaceutical company and limits strategic flexibility. The company has prioritized deleveraging over dividends, cutting the payout from $2.6 per share in 2022 to $0.1 in 2024—the legal minimum. Free cash flow of $3.4 billion in 2024 was positive but is guided to $1.6-2.5 billion for 2025, reflecting continued litigation cash outflows and restructuring costs. The competitive landscape in pharmaceuticals is intensifying. Nubeqa faces competition from Johnson & Johnson's Erleada (apalutamide) and Pfizer/Astellas' Xtandi (enzalutamide) in the androgen receptor inhibitor space. Xtandi faces patent expiry in 2026 (Europe) and 2027 (U.S.), which could create generic pressure but also opens market share for Nubeqa if physicians switch before generic entry. Eylea competes with Regeneron's own aflibercept franchise and Roche's Vabysmo in ophthalmology, where the 8mg formulation provides differentiation but faces pricing pressure from biosimilar competition. Kerendia operates in the crowded SGLT2 inhibitor and mineralocorticoid receptor antagonist space, where Novo Nordisk's Ozempic and Eli Lilly's Mounjaro are reshaping diabetes and cardiovascular treatment paradigms. The organizational transformation under Dynamic Shared Ownership, while necessary, creates execution risk. Anderson has eliminated roughly half of all management positions and reduced hierarchy layers, but the cultural transition from a hierarchical German corporate structure to a decentralized, agile organization is unprecedented in Bayer's history. The 12,000+ headcount reduction has generated savings but also risks losing institutional knowledge and disrupting ongoing operations. The 2024 annual report notes that 'savings generated by the headcount reduction were partially offset by higher expenses for group-wide incentive programs as well as expenses relating to our restructuring programs,' suggesting the net cost reduction is smaller than the headline job cuts imply.